New clinical results support telomerase vaccination in breast cancer
The results show that vaccination with the I540 telomerase peptide led to changes in the tumor microenvironment, infiltration of T-cells and widespread tumor necrosis (tumor death). Furthermore, an exploratory analysis revealed that the median overall survival was significantly longer in those patients who achieved an immune response to the I540 peptide compared to patients who did not. Immune responses to a control peptide did not correlate with survival.
The I540 telomerase peptide and its use in cancer immunotherapy is claimed in Pharmexa's granted European patent. This and other claims on a number of telomerase peptides including GV1001 were recently upheld by the Appeal Board of the European Patent Office.
Original publication: Cancer Research 2007, 67: (21).
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.